Log In
Print
BCIQ
Print
Print this Print this
 

Lipacreon, pancrelipase (Creon) (SA-001)

  Manage Alerts
Collapse Summary General Information
Company Abbott Laboratories
DescriptionPancrelipase delayed-release capsules
Molecular Target
Mechanism of ActionEnzyme replacement therapy
Therapeutic ModalityBiologic: Enzyme
Latest Stage of DevelopmentMarketed
Standard IndicationPancreatic insufficiency
Indication DetailsTreat pancreatic exocrine insufficiency (PEI); Treat pancreatic exocrine insufficiency due due to chronic pancreatitis or pancreatic surgery; Treat pancreatic exocrine insufficiency due to cystic fibrosis (CF)
Regulatory Designation

Partner

AbbVie Inc.; Eisai Co. Ltd.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today